Clinical Trial Update: Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating low-dose rituximab for neuromyelitis optica spectrum disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 4 | Status: COMPLETED